drugset / Trial / NCT01156077

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

NCT01156077

Phase 1 Completed 20 enrolled Merck & Co., Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is an open-label, multi-center, two-part, parallel-design study to assess the PK, safety, and tolerability of TR-701 FA and its active metabolite, TR-700, following a single oral dose (Part A) or IV dose (Part B) of TR-701 FA in 12 to 17 year old adolescent patients.

Timeline

Start
2010-06-02
Primary completion
2011-09-24
Completion
2011-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tedizolid Small molecule 200 mg Oral